Actively Recruiting
Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
Led by Innovent Biologics (Suzhou) Co. Ltd. · Updated on 2025-02-11
190
Participants Needed
10
Research Sites
139 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main purpose of this study is to evaluate the safety and tolerability of IBI3009 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) of IBI3009.
CONDITIONS
Official Title
Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to understand and provide written informed consent for study participation
- Male or female aged 18 to 75 years
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
- Minimum life expectancy of at least 12 weeks
- Adequate organ function confirmed at screening
- Histologically or cytologically confirmed unresectable, metastatic, or extensive-stage small cell lung cancer
You will not qualify if you...
- Participation in other interventional clinical research except observational studies or follow-up phases
- Unresolved adverse reactions from previous anti-tumor therapies above Grade 1 toxicity (except certain conditions like alopecia and fatigue)
- Known allergies or intolerance to IBI3009 or its ingredients
- Major surgery within 4 weeks before first dose or expected during study, or severe unhealed wounds or trauma
- Pregnant or lactating women or positive pregnancy test
- Deemed ineligible by the investigator for any reason
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
Westmead Hospital
Westmead, New South Wales, Australia, 2145
Actively Recruiting
2
Wollongong Hospital
Wollongong, New South Wales, Australia, 2500
Not Yet Recruiting
3
Austin Hospital
Heidelberg, Victoria, Australia, 3084
Actively Recruiting
4
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China, 230022
Not Yet Recruiting
5
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China, 350005
Not Yet Recruiting
6
Henan Cancer Hospital
Zhengzhou, Henan, China, 450000
Not Yet Recruiting
7
Hunan Cancer Hospital
Changsha, Hunan, China, 410000
Actively Recruiting
8
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China, 330006
Not Yet Recruiting
9
Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)
Jinan, Shandong, China, 250117
Not Yet Recruiting
10
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310005
Actively Recruiting
Research Team
L
Lue Shen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here